Oo. The company said it is launching new products that will boost sales, including nine new drug and vaccine approvals this year, and has a strong pipeline of drugs that could add further revenue.
Pfizer also said its deal-making, including an acquisition of cancer-drug biotech Seagen that closed on Thursday, could generate $25 billion in new revenue by 2030.